Randomized, Double-Blind, Phase II Study of FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment for Patients With Metastatic Colorectal Cancer
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Progression-free survival: time from randomization to tumor progression or death, tumor assessments according to RECIST criteria
up to 4 years
No
Clinical Trials
Study Director
Genentech
United States: Food and Drug Administration
GO27827
NCT01418222
September 2011
June 2018
Name | Location |
---|---|
Hinsdale, Illinois 60521 | |
New Britain, Connecticut 06052 | |
Albany, Georgia 31701 | |
Fountain Valley, California 92708 | |
Miami, Florida 33176 | |
Columbia, Missouri 65203 | |
Cleveland, Ohio 44195 | |
Nashville, Tennessee 37203-1632 | |
Austin, Texas 78705 | |
Louisville, Kentucky 40207 | |
McLean, Virginia 22101 | |
Hackensack, New Jersey 07601 | |
Denver, Colorado | |
Baltimore, Maryland 21287 | |
Charleston, South Carolina | |
Tulsa, Oklahoma |